Analysis of BRAF V600E expression and disease-free survival in patients with ameloblastoma

Kunmongkolwut, Sumana; Chaisuparat, Risa

doi:10.1016/j.ijom.2021.12.011

Cited by 12 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Duplicate references were removed and the remaining titles and abstracts analyzed. Forty‐six articles were selected for full‐text analysis, with 21 9,10,12,16–33 studies meeting the criteria to be included in this systematic review. The PRISMA flow diagram showing the complete article selection process is illustrated in Figure S1.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta‐analysis

Barros

Silva

Gonçalves

et al. 2023

J Oral Pathology Medicine

View full text Add to dashboard Cite

ObjectiveThe objective of this systematic review with meta‐analysis was to critically evaluate the available data on the association of the BRAF V600E mutation and recurrence rate of ameloblastomas.Materials and MethodsThis systematic review was registered in Prospero (CRD42020183645) and performed based on the PRISMA statement. A comprehensive search in PubMed, Web of Science, Scopus and Cochrane Library databases was performed in order to answer the question “Does BRAF V600E mutation affect recurrence rate of ameloblastomas?” Methodological quality and risk of bias of the selected studies were assessed with JBI Critical Appraise Tool. Meta‐analysis of quantitative data was conducted with RevMan 5.3 and Jamovi 2.3.ResultsThe initial search identified 302 articles, and 21 met the inclusion criteria. A total of 855 subjects with ameloblastoma were included in the analysis. The pooled measures for frequency of BRAF V600E mutation was 65.30% (95% CI: 0.56–0.75; p < .001; I2 = 90.85%; τ = 0.205; p < .001), and the pooled recurrence rate was 25.30% (95% CI: 0.19–0.31; p < .001; I2 = 79.44%; τ = 0.118; p < .001). No differences in recurrence rate were observed between the BRAF V600E and wild type BRAF ameloblastomas, with a pooled Odds Ratio of 0.93 (95% CI: 0.56–1.54; p = .78; I2 = 31%; p = .09).ConclusionsBRAF V600E mutation is a frequent event in ameloblastomas, but does not increase nor reduce its recurrence rate, and thus have a limited value in predicting its prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Duplicate references were removed and the remaining titles and abstracts analyzed. Forty-six articles were selected for full-text analysis, with 21 9,10,12,[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]…”

Section: Literature Searchmentioning

confidence: 99%

Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta‐analysis

Barros

Silva

Gonçalves

et al. 2023

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…Only the minimum 50% of the elements in each domain were accounted for as an A score. Six studies were evaluated with an A score for nine domains [ 6 , 9 , 18 , 19 , 20 , 21 ], six studies with an A score for eight out of nine domains [ 22 , 23 , 24 , 25 , 26 , 27 ], three studies with an A score for seven out of nine domains [ 5 , 11 , 28 ], and two studies with an A score for six out of nine domains [ 29 , 30 ].…”

Section: Resultsmentioning

confidence: 99%

“…The final 17 studies were included for qualitative and quantitative analysis with a total of 833 patients. The research by Sweeney et al in 2014 was the earliest study, and the latest publication was in 2022, by Kunmongkolwut and colleagues [ 26 ]. The most extensive study was by da Silva Marcelino et al [ 25 ] and included 128 patients; the lowest number of samples was by Yukimori et al [ 30 ], with 14 patients.…”

Section: Resultsmentioning

confidence: 99%

“…The total number of BRAF mutations for further analysis includes the number of positive mutations detected by polymerase chain reaction (PCR) [ 5 , 9 , 11 , 19 , 21 , 22 , 24 , 29 , 30 ], and data from immunohistochemistry (IHC) results whereby IHC was the sole method available in seven individual studies [ 18 , 20 , 23 , 25 , 26 , 27 , 28 ] ( Table 3 ). For Brown et al’s [ 6 ] study, IHC data were used because not all cases had PCR data; moreover, for cases with both IHC and PCR data, 100% concordance was recorded for both methods in this individual study.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis

Yusof

Ch’ng

Rahman

2022

Cancers

View full text Add to dashboard Cite

The discovery that ameloblastoma has a high mutation incidence of BRAF V600E may enable a better investigation of pathophysiology. However, there is inconsistent evidence regarding this mutation occurrence and its association with clinical information. This systematic review and meta-analysis aim to pool the overall mutation prevalence of BRAF V600E in reported ameloblastoma cases and to determine its association with patient demographic and clinicopathological features. Following the PRISMA guidelines, a comprehensive article search was conducted through four databases (Scopus, Google Scholar, PubMed, and Web of Science). Seventeen articles between 2014 and 2022 met the inclusion criteria with 833 ameloblastoma cases. For each included study, the significance of BRAF V600E on the outcome parameters was determined using odd ratios and 95% confidence intervals. Meta-analysis prevalence of BRAF V600E in ameloblastoma was 70.49%, and a significant meta-analysis association was reported for those younger than 54 years old and in the mandible. On the contrary, other factors, such as sex, histological variants, and recurrence, were insignificant. As a result of the significant outcome of BRAF V600E mutation in ameloblastoma pathogenesis, targeted therapy formulation can be developed with this handful of evidence.

show abstract